Tetrahydropalmatine

Tetrahydropalmatine (THP), also known as rotundine, is a tetrahydroprotoberberine isoquinoline alkaloid isolated from tubers of Corydalis yanhusuo (Yan Hu Suo) and roots of Stephania rotunda, two genera of the Papaveraceae and Menispermaceae families with extensive histories in traditional Chinese and Southeast Asian medicine. The compound exists as two enantiomers: levo-tetrahydropalmatine (l-THP, the 13aR configuration) and dextro-tetrahydropalmatine (d-THP, the 13aS configuration), as well as the racemic mixture (dl-THP). The levorotatory enantiomer is the principal pharmacologically active form and has been manufactured as a pharmaceutical product in China under the name rotundine for the treatment of pain and insomnia since the mid-twentieth century. Molecular pharmacology studies have established that l-THP acts as a moderate-affinity antagonist at dopamine D1 receptors (Ki approximately 124 nM), dopamine D2 receptors (Ki approximately 388 nM), and dopamine D3 receptors, with additional binding at serotonin 5-HT1A receptors (Ki approximately 340 nM), alpha-1 adrenergic receptors, and modulatory effects on GABAergic neurotransmission through enhancement of GABA-A receptor activity. This multi-target monoaminergic profile distinguishes tetrahydropalmatine from conventional dopamine antagonists and underwrites the compound's diverse pharmacological actions: analgesia in inflammatory and neuropathic pain models, sedation and anxiolysis, attenuation of drug-seeking behavior in cocaine, heroin, and nicotine self-administration paradigms, and anti-inflammatory activity through suppression of NF-kappaB signaling and proinflammatory cytokine release.

Pharmacokinetics in humans are characterized by rapid absorption (absorption half-life approximately 0.5 hours), rapid distribution (distribution half-life approximately 0.74 hours), and slow elimination (elimination half-life approximately 11.4 hours). Oral bioavailability is low due to extensive first-pass hepatic metabolism, principally through CYP3A and CYP1A2 isoforms, with stereoselective differences between enantiomers. Self-microemulsifying drug delivery systems have demonstrated a 3.25-fold improvement in relative bioavailability compared with conventional suspension formulations. The compound crosses the blood-brain barrier and achieves central nervous system concentrations sufficient for dopaminergic and serotonergic receptor modulation at therapeutic oral doses.

Clinical evidence is modest but growing. A randomized, double-blind, placebo-controlled Phase 1 study in cocaine users (2016) established the safety and tolerability of a 3.5-day oral l-THP course. A pilot clinical study in heroin-dependent patients demonstrated that one-month l-THP treatment significantly reduced opiate craving and enhanced the abstinence rate three-fold at three months post-discharge. A randomized controlled trial of l-THP as adjunctive treatment for schizophrenia (NCT02118610, published 2020) did not demonstrate significant improvement in psychiatric symptoms at 30 mg in the published literature for four weeks, though the study confirmed tolerability and absence of serious adverse events. The compound has been marketed as a sedative-analgesic in China for decades and is under active investigation in the United States and Vietnam for substance use disorders.

The principal safety signals are sedation (dose-dependent, reflecting the composite dopaminergic and GABAergic mechanism), hepatotoxicity (reported in association with herbal preparations containing l-THP, though causality is confounded by product adulteration and polypharmacy), and rare acute poisoning characterized by mild neurological disturbance with rapid recovery. This monograph documents the chemistry, stereochemistry, and natural sources of tetrahydropalmatine; the multi-receptor pharmacology in molecular and behavioral detail; the pharmacokinetic record including CYP isoform involvement and bioavailability optimization; the preclinical pharmacology across pain, addiction, neuroinflammation, and neuroprotection models; the clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signal; and a comparative assessment of five alternative analgesic or dopaminergic compounds against tetrahydropalmatine on five competency standards.